Dasatinib for the treatment of chronic myeloid leukemia

Amber Fullmer, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Research output: Contribution to journalArticle

Abstract

Earlier use of more potent tyrosine kinase inhibitors such as dasatinib improves response rates for patients with chronic myeloid leukemia (CML). The SRC-ABL Tyrosine Kinase Inhibition Activity Research Trials series displayed dasatinib efficacy in patients with all phases of CML who are resistant or intolerant to imatinib. More recently, dasatinib has been shown to induce rapid and high rates of response and has gained approval for newly diagnosed patients with CML in chronic phase. The future of CML therapy may incorporate more potent tyrosine kinase inhibitors such as dasatinib into initial treatment for newly diagnosed patients. The ability of dasatinib to induce rapid and high rates of response with a low progression to advanced forms of CML may translate into improvements in survival.

Original languageEnglish (US)
Pages (from-to)253-260
Number of pages8
JournalExpert Review of Hematology
Volume4
Issue number3
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Leukemia, Myeloid, Chronic Phase
Therapeutics
Dasatinib
Survival
Research

Keywords

  • chronic myeloid leukemia
  • dasatinib
  • imatinib
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Dasatinib for the treatment of chronic myeloid leukemia. / Fullmer, Amber; Kantarjian, Hagop; Cortes, Jorge; Jabbour, Elias.

In: Expert Review of Hematology, Vol. 4, No. 3, 01.06.2011, p. 253-260.

Research output: Contribution to journalArticle

Fullmer, Amber ; Kantarjian, Hagop ; Cortes, Jorge ; Jabbour, Elias. / Dasatinib for the treatment of chronic myeloid leukemia. In: Expert Review of Hematology. 2011 ; Vol. 4, No. 3. pp. 253-260.
@article{1fe6433209004d5eb4fd3e946dd5a2e2,
title = "Dasatinib for the treatment of chronic myeloid leukemia",
abstract = "Earlier use of more potent tyrosine kinase inhibitors such as dasatinib improves response rates for patients with chronic myeloid leukemia (CML). The SRC-ABL Tyrosine Kinase Inhibition Activity Research Trials series displayed dasatinib efficacy in patients with all phases of CML who are resistant or intolerant to imatinib. More recently, dasatinib has been shown to induce rapid and high rates of response and has gained approval for newly diagnosed patients with CML in chronic phase. The future of CML therapy may incorporate more potent tyrosine kinase inhibitors such as dasatinib into initial treatment for newly diagnosed patients. The ability of dasatinib to induce rapid and high rates of response with a low progression to advanced forms of CML may translate into improvements in survival.",
keywords = "chronic myeloid leukemia, dasatinib, imatinib, tyrosine kinase inhibitor",
author = "Amber Fullmer and Hagop Kantarjian and Jorge Cortes and Elias Jabbour",
year = "2011",
month = "6",
day = "1",
doi = "10.1586/ehm.11.20",
language = "English (US)",
volume = "4",
pages = "253--260",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Dasatinib for the treatment of chronic myeloid leukemia

AU - Fullmer, Amber

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Jabbour, Elias

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Earlier use of more potent tyrosine kinase inhibitors such as dasatinib improves response rates for patients with chronic myeloid leukemia (CML). The SRC-ABL Tyrosine Kinase Inhibition Activity Research Trials series displayed dasatinib efficacy in patients with all phases of CML who are resistant or intolerant to imatinib. More recently, dasatinib has been shown to induce rapid and high rates of response and has gained approval for newly diagnosed patients with CML in chronic phase. The future of CML therapy may incorporate more potent tyrosine kinase inhibitors such as dasatinib into initial treatment for newly diagnosed patients. The ability of dasatinib to induce rapid and high rates of response with a low progression to advanced forms of CML may translate into improvements in survival.

AB - Earlier use of more potent tyrosine kinase inhibitors such as dasatinib improves response rates for patients with chronic myeloid leukemia (CML). The SRC-ABL Tyrosine Kinase Inhibition Activity Research Trials series displayed dasatinib efficacy in patients with all phases of CML who are resistant or intolerant to imatinib. More recently, dasatinib has been shown to induce rapid and high rates of response and has gained approval for newly diagnosed patients with CML in chronic phase. The future of CML therapy may incorporate more potent tyrosine kinase inhibitors such as dasatinib into initial treatment for newly diagnosed patients. The ability of dasatinib to induce rapid and high rates of response with a low progression to advanced forms of CML may translate into improvements in survival.

KW - chronic myeloid leukemia

KW - dasatinib

KW - imatinib

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79959190380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959190380&partnerID=8YFLogxK

U2 - 10.1586/ehm.11.20

DO - 10.1586/ehm.11.20

M3 - Article

C2 - 21668392

AN - SCOPUS:79959190380

VL - 4

SP - 253

EP - 260

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 3

ER -